2024-06-05 11:46:27 ET
Summary
- Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024.
- The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD.
- The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033.
- MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA.
Mind Medicine (MindMed) Inc. ( MNMD ) is a biotech that should be on everyone's watch list. The reason why I state this is that it has been able to make substantial improvements in the MDMA treatment space against certain types of disorders....
Read the full article on Seeking Alpha
For further details see:
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors